ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,460.48
-0.41%
Dow Jones
39,118.86
-0.12%
US Dollar vs MXN
18.3385
0.00%
Brent Oil
84.85
0.00%
Bitcoin
60,691.70
0.63%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Gpc Biotech AG ADS (MM) (GPCB)

  7. Gpc Biotech AG ADS (MM) (GPCB) Noticias

GPCB

Gpc Biotech AG ADS (MM) (GPCB)

Gpc Biotech AG ADS (MM)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GPCB
FechaHoraFuenteTítuloSímboloCompañía
21/04/200909:12Business WireNew Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACRNASDAQ:GPCBGpc Biotech AG ADS (MM)
25/03/200901:40Business WireGPC Biotech Reports Financial Results for Fiscal Year 2008NASDAQ:GPCBGpc Biotech AG ADS (MM)
23/02/200913:17Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:GPCBGpc Biotech AG ADS (MM)
17/02/200919:31Business WireGPC Biotech and Agennix Announce Proposed MergerNASDAQ:GPCBGpc Biotech AG ADS (MM)
09/12/200803:10Business WireGPC Biotech Opens Enrollment in Phase 1 Trial Evaluating RGB-286638 Multi-Targeted Protein Kinase Inhibitor in Patients with ...NASDAQ:GPCBGpc Biotech AG ADS (MM)
13/11/200800:40Business WireGPC Biotech Reports Financial Results For Third Quarter and First Nine Months of 2008NASDAQ:GPCBGpc Biotech AG ADS (MM)
06/11/200808:42Business WireGPC Biotech to Present at Rodman & Renshaw Annual Global Investment Conference in New YorkNASDAQ:GPCBGpc Biotech AG ADS (MM)
25/08/200814:13Edgar (US Regulatory)Gpc Biotech Ag - Report of Foreign Issuer (6-K)NASDAQ:GPCBGpc Biotech AG ADS (MM)
06/08/200817:01Business WireGPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for SatraplatinNASDAQ:GPCBGpc Biotech AG ADS (MM)
25/07/200815:15Business WireGPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be WithdrawnNASDAQ:GPCBGpc Biotech AG ADS (MM)
12/06/200803:05Business WireGPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to TaxanesNASDAQ:GPCBGpc Biotech AG ADS (MM)
05/06/200801:49Business WireGPC Biotech to Present at Two Upcoming Conferences: 7th Annual Needham Biotechnology & Medical Technology Conference in New YorkNASDAQ:GPCBGpc Biotech AG ADS (MM)
02/06/200802:06Business WireData from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial ChemotheNASDAQ:GPCBGpc Biotech AG ADS (MM)
02/06/200802:05Business WireNew Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual MeetingNASDAQ:GPCBGpc Biotech AG ADS (MM)
28/05/200802:07Business WireGPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual MeetingNASDAQ:GPCBGpc Biotech AG ADS (MM)
15/05/200801:36Business WireGPC Biotech Reports Financial Results for First Quarter 2008NASDAQ:GPCBGpc Biotech AG ADS (MM)
31/01/200812:42Edgar (US Regulatory)Gpc Biotech Ag - Amended Statement of Ownership (SC 13G/A)NASDAQ:GPCBGpc Biotech AG ADS (MM)
30/10/200722:35PR Newswire (US)GPC Biotech Today Announced Results of Survival Analysis from the SPARC TrialNASDAQ:GPCB
30/10/200722:27PR Newswire (US)Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 TrialNASDAQ:GPCB
28/09/200710:12Edgar (US Regulatory)Gpc Biotech Ag (Other) (SC 13G)NASDAQ:GPCBGpc Biotech AG ADS (MM)
23/08/200717:00PR Newswire (US)Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLPNASDAQ:GPCBGpc Biotech AG ADS (MM)
23/08/200700:58PR Newswire (US)GPC Biotech Announces RestructuringNASDAQ:GPCB
21/08/200709:41PR Newswire (US)Finkelstein Thompson LLP Announces GPC Biotech AG InvestigationNASDAQ:GPCBGpc Biotech AG ADS (MM)
08/08/200701:37PR Newswire (US)GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2007NASDAQ:GPCB
02/08/200705:05PR Newswire (US)GPC Biotech Schedules Conference Call on August 8th to Discuss First Half 2007 Financial ResultsNASDAQ:GPCB
30/07/200708:57PR Newswire (US)GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated ApprovalNASDAQ:GPCB
30/07/200708:48PR Newswire (US)GPC Biotech Withdraws Satraplatin NDA For Accelerated Approval; Plans to Resubmit With Survival AnalysisNASDAQ:GPCB
27/07/200721:30PR Newswire (US)Law Offices of Howard G. Smith Announces Class Action Lawsuit Against GPC BiotechNASDAQ:GPCBGpc Biotech AG ADS (MM)
27/07/200713:05PR Newswire (US)GPC Biotech AG Named in Purported Class Action Lawsuit in the United StatesNASDAQ:GPCB
27/07/200706:00PR Newswire (US)Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines AgencyNASDAQ:GPCB
 Showing the most relevant articles for your search:NASDAQ:GPCB

Su Consulta Reciente

BIT
F24410
Vontobel Financial Produ...
LSE
79EL
Euro.bk. 24
ASX
EAFN
NYSE
NEE-P
NextEra Energy
BIT
UB48HG
Unicredit Bank
TSXV
SURF.A
Starlight US Residential
BIT
UC6M32
Unicredit Bank
BOV
BUSR39Q
CORE US REITDRN
BIT
UC527K
Unicredit Bank
EU
1756T
1756T
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados